BTK and hematopoietic and lymphoid cell neoplasm: Currently, five BTK inhibitors—ibrutinib, zanubrutinib, orelabrutinib, tirabrutinib, and acalabrutinib—have demonstrated remarkable efficacy and have been approved for the treatment of different types of hematological cancers (5).